Last reviewed · How we verify
Vadebex (NOSCAPINE)
Vadebex works by inhibiting microtubule dynamics, which can lead to cell cycle arrest and apoptosis in cancer cells.
Vadebex, also known as noscapine, is a small molecule drug that targets the Cytochrome P450 2C19 enzyme. It is a noscapine drug class, but its commercial status and approved indications are unknown. The drug has a half-life of 2.13 hours and bioavailability of 30%. As a noscapine drug, its mechanism of action is not fully understood, but it is thought to work by inhibiting microtubule dynamics, which can lead to cell cycle arrest and apoptosis in cancer cells. Further research is needed to fully understand its effects and potential uses.
At a glance
| Generic name | NOSCAPINE |
|---|---|
| Drug class | noscapine |
| Target | Cytochrome P450 2C19, Cytochrome P450 2C9, Multidrug and toxin extrusion protein 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Imagine your cells are like a factory with many moving parts. Vadebex works by disrupting the tiny 'roads' that these parts move along, which can cause the factory to shut down and eventually die. This can be helpful in treating certain types of cancer.
Approved indications
Common side effects
- Toxicity to various agents
- Drug abuse
Key clinical trials
- A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma (PHASE1)
- Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |